Currently out of the existing stock ratings of Kemp Dolliver, 9 are a BUY (75%), 3 are a HOLD (25%).

Kemp Dolliver

Work Performance Price Targets & Ratings Chart

Analyst Kemp Dolliver, currently employed at BROOKLINE, carries an average stock price target met ratio of 38.89% that have a potential upside of 18.14% achieved within 37 days.

Kemp Dolliver’s has documented 22 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on YMAB, Y mAbs Therapeutics at 03-Mar-2025.

Wall Street Analyst Kemp Dolliver

Analyst best performing recommendations are on VRCA (VERRICA PHARMACEUTICALS).
The best stock recommendation documented was for VRCA (VERRICA PHARMACEUTICALS) at 3/9/2022. The price target of $20 was fulfilled within 78 days with a profit of $59.6 (74.87%) receiving and performance score of 9.6.

Average potential price target upside

ECOR Electrocore LLC VRCA Verrica Pharmaceuticals PNT POINT Biopharma Global ONCT Oncternal Therapeutics DARE Dare Bioscience EYEN Eyenovia BLPH Bellerophon Therapeutics YMAB Y mAbs Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$25

$20.09 (409.16%)

$25

7 months 6 days ago
(13-Mar-2025)

6/9 (66.67%)

$15.45 (161.78%)

421

Buy

$1.25

$-5.56 (-81.64%)

2 years 9 months 7 days ago
(13-Jan-2023)

0/1 (0%)

$-3.28 (-72.41%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Kemp Dolliver?

On 2021

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?